JP2021525084A5 - - Google Patents
Info
- Publication number
- JP2021525084A5 JP2021525084A5 JP2020565431A JP2020565431A JP2021525084A5 JP 2021525084 A5 JP2021525084 A5 JP 2021525084A5 JP 2020565431 A JP2020565431 A JP 2020565431A JP 2020565431 A JP2020565431 A JP 2020565431A JP 2021525084 A5 JP2021525084 A5 JP 2021525084A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleoside
- nephropathy
- pharmaceutically acceptable
- compound
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023040313A JP7645301B2 (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
| JP2024194079A JP2025013513A (ja) | 2018-05-22 | 2024-11-06 | Ａｐｏｌ１発現のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674865P | 2018-05-22 | 2018-05-22 | |
| US62/674,865 | 2018-05-22 | ||
| PCT/US2019/033244 WO2019226611A1 (en) | 2018-05-22 | 2019-05-21 | Modulators of apol1 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040313A Division JP7645301B2 (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525084A JP2021525084A (ja) | 2021-09-24 |
| JP2021525084A5 true JP2021525084A5 (enExample) | 2022-03-24 |
| JP7247227B2 JP7247227B2 (ja) | 2023-03-28 |
Family
ID=68613945
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565431A Active JP7247227B2 (ja) | 2018-05-22 | 2019-05-21 | Ａｐｏｌ１発現のモジュレーター |
| JP2023040313A Active JP7645301B2 (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
| JP2024194079A Pending JP2025013513A (ja) | 2018-05-22 | 2024-11-06 | Ａｐｏｌ１発現のモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040313A Active JP7645301B2 (ja) | 2018-05-22 | 2023-03-15 | Ａｐｏｌ１発現のモジュレーター |
| JP2024194079A Pending JP2025013513A (ja) | 2018-05-22 | 2024-11-06 | Ａｐｏｌ１発現のモジュレーター |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10927377B2 (enExample) |
| EP (1) | EP3799570A4 (enExample) |
| JP (3) | JP7247227B2 (enExample) |
| KR (2) | KR20250153881A (enExample) |
| CN (3) | CN118127019A (enExample) |
| AR (1) | AR115416A1 (enExample) |
| AU (2) | AU2019274461B2 (enExample) |
| BR (1) | BR112020023436A2 (enExample) |
| CA (1) | CA3099750A1 (enExample) |
| CL (1) | CL2020003010A1 (enExample) |
| CO (1) | CO2020015377A2 (enExample) |
| CR (1) | CR20200631A (enExample) |
| EA (1) | EA202092748A1 (enExample) |
| EC (1) | ECSP20082339A (enExample) |
| IL (2) | IL316397A (enExample) |
| JO (1) | JOP20200291A1 (enExample) |
| MA (1) | MA53924A (enExample) |
| MX (2) | MX2020012497A (enExample) |
| MY (1) | MY200352A (enExample) |
| NI (1) | NI202000085A (enExample) |
| PE (1) | PE20211397A1 (enExample) |
| PH (1) | PH12020551995A1 (enExample) |
| SG (1) | SG11202011397QA (enExample) |
| TW (2) | TWI841564B (enExample) |
| UA (1) | UA128819C2 (enExample) |
| WO (1) | WO2019226611A1 (enExample) |
| ZA (1) | ZA202007537B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49076E1 (en) | 2010-04-18 | 2022-05-17 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| IL316397A (en) | 2018-05-22 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of APOL1 expression |
| IL283592B2 (en) | 2018-12-17 | 2025-08-01 | Vertex Pharma | Inhibitors of apol1 and methods of using same |
| EP4097083A1 (en) | 2020-01-29 | 2022-12-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
| CN116157393A (zh) | 2020-06-12 | 2023-05-23 | 弗特克斯药品有限公司 | Apol1的抑制剂及其用途 |
| EP4165036A1 (en) | 2020-06-12 | 2023-04-19 | Vertex Pharmaceuticals Incorporated | Solid forms of apol1 inhibitor and using the same |
| KR20240149461A (ko) | 2022-01-18 | 2024-10-14 | 메이즈 테라퓨틱스, 인코퍼레이티드 | Apol1 저해제 및 사용 방법 |
| EP4573077A1 (en) * | 2022-08-19 | 2025-06-25 | Maze Therapeutics, Inc. | Apol1 inhibitors and methods of use |
| TW202545540A (zh) | 2024-05-21 | 2025-12-01 | 瑞典商阿斯特捷利康公司 | 用於治療ａｐｏｌ１介導之腎病之方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082401A1 (en) | 1994-12-15 | 2002-06-27 | Yeda Research And Development Company | Modulators of the function of FAS/APO1 receptors |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| WO2002028999A2 (en) | 2000-10-03 | 2002-04-11 | Gene Logic, Inc. | Gene expression profiles in granulocytic cells |
| USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
| US20070054278A1 (en) | 2003-11-18 | 2007-03-08 | Applera Corporation | Polymorphisms in nucleic acid molecules encoding human enzyme proteins, methods of detection and uses thereof |
| US20050171044A1 (en) | 2003-12-24 | 2005-08-04 | Stein David A. | Oligonucleotide compound and method for treating nidovirus infections |
| WO2006034348A2 (en) | 2004-09-17 | 2006-03-30 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| EP1867338A1 (en) | 2006-05-30 | 2007-12-19 | Université Libre De Bruxelles | Pharmaceutical composition comprising apolipoproteins for the treatment of human diseases |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| CA2739464C (en) | 2008-10-03 | 2020-03-31 | Curna, Inc. | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1 |
| CN102307997B (zh) | 2008-12-04 | 2018-03-30 | 库尔纳公司 | 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病 |
| WO2011020865A1 (en) | 2009-08-18 | 2011-02-24 | Universite Libre De Bruxelles | Apolipoprotein l- i variants and their use |
| JP5991922B2 (ja) | 2009-11-13 | 2016-09-14 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンス抗ウイルス性化合物およびインフルエンザウイルス感染を処置するための方法 |
| JP6031356B2 (ja) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー，インコーポレイテッド | Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療 |
| US9023355B2 (en) * | 2010-04-13 | 2015-05-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating renal disease |
| US20120003644A1 (en) | 2010-06-07 | 2012-01-05 | Rappaport Family Institute For Research In The Medical Sciences | Methods and kits for determining predisposition to develop kidney diseases |
| CA2863958A1 (en) * | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating factor vii expression |
| HUE051680T2 (hu) | 2012-05-24 | 2021-03-29 | Ionis Pharmaceuticals Inc | Apolipoprotein(a) expressziójának módosítására szolgáló eljárások és készítmények |
| WO2014078213A2 (en) | 2012-11-16 | 2014-05-22 | Merck Sharp & Dohme Corp. | Modified apol1 polypeptides |
| WO2014085154A1 (en) | 2012-11-27 | 2014-06-05 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| US20160003808A1 (en) | 2013-03-14 | 2016-01-07 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| GB201311057D0 (en) | 2013-06-21 | 2013-08-07 | Univ Greenwich | Antisense oligonucleotide compositions |
| TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| CN116970607A (zh) | 2014-03-19 | 2023-10-31 | Ionis制药公司 | 用于调节共济失调蛋白2表达的组合物 |
| EP3020813A1 (en) | 2014-11-16 | 2016-05-18 | Neurovision Pharma GmbH | Antisense-oligonucleotides as inhibitors of TGF-R signaling |
| TW201718010A (zh) * | 2015-06-19 | 2017-06-01 | 健臻公司 | 治療原發性局部節段性腎小球硬化症之方法 |
| IL318703A (en) | 2015-06-29 | 2025-03-01 | Caris Science Inc | Therapeutic oligonucleotides |
| HK1255699A1 (zh) * | 2015-09-24 | 2019-08-23 | Ionis Pharmaceuticals, Inc. | Kras表达的调节剂 |
| IL316397A (en) | 2018-05-22 | 2024-12-01 | Ionis Pharmaceuticals Inc | Modulators of APOL1 expression |
-
2019
- 2019-05-21 IL IL316397A patent/IL316397A/en unknown
- 2019-05-21 CN CN202410386618.XA patent/CN118127019A/zh active Pending
- 2019-05-21 TW TW108117504A patent/TWI841564B/zh active
- 2019-05-21 EA EA202092748A patent/EA202092748A1/ru unknown
- 2019-05-21 CN CN202410386621.1A patent/CN118127020A/zh active Pending
- 2019-05-21 US US16/418,060 patent/US10927377B2/en active Active
- 2019-05-21 AU AU2019274461A patent/AU2019274461B2/en active Active
- 2019-05-21 WO PCT/US2019/033244 patent/WO2019226611A1/en not_active Ceased
- 2019-05-21 PE PE2020001880A patent/PE20211397A1/es unknown
- 2019-05-21 KR KR1020257034730A patent/KR20250153881A/ko active Pending
- 2019-05-21 EP EP19807789.3A patent/EP3799570A4/en active Pending
- 2019-05-21 SG SG11202011397QA patent/SG11202011397QA/en unknown
- 2019-05-21 CN CN201980033544.9A patent/CN112423792B/zh active Active
- 2019-05-21 MY MYPI2020006084A patent/MY200352A/en unknown
- 2019-05-21 JO JOP/2020/0291A patent/JOP20200291A1/ar unknown
- 2019-05-21 CR CR20200631A patent/CR20200631A/es unknown
- 2019-05-21 KR KR1020207036583A patent/KR102874776B1/ko active Active
- 2019-05-21 IL IL278785A patent/IL278785B2/en unknown
- 2019-05-21 CA CA3099750A patent/CA3099750A1/en active Pending
- 2019-05-21 UA UAA202007818A patent/UA128819C2/uk unknown
- 2019-05-21 MX MX2020012497A patent/MX2020012497A/es unknown
- 2019-05-21 BR BR112020023436-2A patent/BR112020023436A2/pt unknown
- 2019-05-21 JP JP2020565431A patent/JP7247227B2/ja active Active
- 2019-05-21 TW TW113114934A patent/TW202430638A/zh unknown
- 2019-05-21 MA MA053924A patent/MA53924A/fr unknown
- 2019-05-22 AR ARP190101365A patent/AR115416A1/es unknown
-
2020
- 2020-09-18 US US17/025,239 patent/US11525136B2/en active Active
- 2020-11-18 PH PH12020551995A patent/PH12020551995A1/en unknown
- 2020-11-19 CL CL2020003010A patent/CL2020003010A1/es unknown
- 2020-11-20 NI NI202000085A patent/NI202000085A/es unknown
- 2020-11-20 MX MX2025003294A patent/MX2025003294A/es unknown
- 2020-12-03 ZA ZA2020/07537A patent/ZA202007537B/en unknown
- 2020-12-09 CO CONC2020/0015377A patent/CO2020015377A2/es unknown
- 2020-12-18 EC ECSENADI202082339A patent/ECSP20082339A/es unknown
-
2022
- 2022-11-08 US US18/053,447 patent/US12168766B2/en active Active
-
2023
- 2023-03-15 JP JP2023040313A patent/JP7645301B2/ja active Active
-
2024
- 2024-11-06 JP JP2024194079A patent/JP2025013513A/ja active Pending
- 2024-11-07 US US18/939,901 patent/US20250066785A1/en active Pending
-
2025
- 2025-10-31 AU AU2025259982A patent/AU2025259982A1/en active Pending